 |
 |
|
|
Thyroid Cancer Clinical Trials |
|
|
Written by Administrator
|
|
Monday, 12 December 2005 |
Thyroid Cancer Clinical TrialsFor information about current clinical research trials for thyroid cancer and other diseases, go to the following U.S. Government website: http://www.clinicaltrials.gov. This is the website for the U.S. Government's Clinical Trials Database. This database provides information about clinical research trials for thyroid cancer and other diseases. This list describes clinical trials that are recruiting new participants. The National Institutes of Health, through its National Library of Medicine, developed this database and web site. The goal of this database is to provide patients, family members, and members of the public with current information about clinical research studies. The NCI PDQ Web Site: Current, Closed, and Past Clinical Trials The following U.S. Government web site lists current clinical trials, as well as completed clinical research trials and studies that are ongoing but that are not recruiting new participants: http://www.cancer.gov/search/clinical_trials/ Ten Things to Know About Treatment Clinical Trials From the National Cancer Institute, National Institutes of Health Bethesda, Maryland NIH Publication No. 00-4830 - Clinical trials are research studies that involve people. Each study tries to answer scientific questions and to find better ways to prevent, diagnose, or treat cancer.
- In cancer research a clinical trial is designed to show how a particular anticancer strategy—for instance, a promising drug, a gene therapy treatment, a new diagnostic test, or a possible way to prevent cancer—affects the people who receive it.
- A clinical trial is one of the stages of a long and careful cancer research process. Getting promising results from testing a new drug on mice, for example, is a preliminary step to human research studies. Treatments that work well in mice do not always work well in people.
- People can benefit from clinical trials. In treatment trials, for example, participants receive high-quality cancer care—and will be among the first to benefit if a new approach is proven to work.
- Only eligible people can participate in a clinical trial. Each study has its own guidelines for who can participate. Generally, participants are alike in key ways—such as the type and stage of cancer, age, gender, and other factors.
- There may be drawbacks. New treatments under study are not always better than, or even as good as, standard care. And they may have unexpected side effects. Through a process called “informed consent” you will learn about a study’s treatments and tests, and their possible benefits and risks, before deciding whether or not to participate.
- In treatment trials involving people who have cancer, placebos are very rarely used.
- Many treatment trials are designed to compare a new treatment with a standard treatment, which is the best treatment currently known for a cancer, based on results of past research. In these studies patients are randomly assigned to one group or another.
- Clinical trials take place all over the country—in cancer centers, other major medical centers, community hospitals and clinics, physicians’ offices and veterans’ and military hospitals.
- Health plans and managed care providers do not always cover all patient care costs in a study. What they cover varies by plan and by study. Ask a doctor, nurse, or social worker form the study to help you determine in advance what costs are covered. The research costs, such as data management, are covered by the study sponsor.
|
|
|
 |
 |
 |
|
|
|
|
|
|
|
Slick RSS |
|
Cancer / Oncology News From Medical News Today
|
|
Latest Cancer / Oncology News From Medical News Today. |
-
UCB And WILEX To Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
UCB Pharma S.A. (UCB) and WILEX AG, a company specialising in the development of drugs and diagnostic agents for cancer (WILEX), today announced that they have agreed to enter into a strategic partnership. WILEX will acquire world-wide rights to develop UCB's entire preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes.
-
Marshall Edwards, Inc. Granted Investigative New Drug For Triphendiol
Marshall Edwards, Inc. (NASDAQ: MSHL) announced that it has been granted an Investigative New Drug (IND) approval by the United States Food and Drug Administration to undertake clinical studies with triphendiol as a chemosensitising agent in combination with gemcitabine. This approval will enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile...
-
Missouri Expands Health Services For Low-Income Women
Missouri has expanded a program to provide state-funded women's health services -- including pelvic exams, cancer screenings and family planning services -- to low-income women without private health insurance, the AP/Washington Examiner reports. The program is available to women ages 18 to 55 with incomes up to 185% of the federal poverty level.
-
Why Bladder Cancer Is Deadlier For Some
Bladder cancer is much more likely to be deadly for women and African-Americans, but the reasons long believed to explain the phenomenon account for only part of the differences for such patients compared to their white and male counterparts, according to results published in the Jan. 1 issue of the journal Cancer.
-
Novel Vaccine Taking Aim At Cancer Cell "Sweet Spot"
Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others. Armed with a new two-year grant for $600,000 from the Gateway for Cancer Research, an Illinois-based philanthropic foundation, immunologist Alessandra Franco, M.D., Ph.D.
|
|
|
|